傲农生物
(603363)
| 流通市值：56.46亿 | | | 总市值：71.83亿 |
| 流通股本：21.47亿 | | | 总股本：27.31亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,022,468,415.78 | 4,520,952,423.17 | 2,205,836,627.38 | 8,474,746,757.55 |
| 营业收入 | 7,022,468,415.78 | 4,520,952,423.17 | 2,205,836,627.38 | 8,474,746,757.55 |
| 二、营业总成本 | 7,529,141,696.14 | 4,818,822,983.52 | 2,283,918,745.89 | 8,694,992,727.85 |
| 营业成本 | 6,929,259,066.33 | 4,445,415,079.55 | 2,112,067,359.48 | 7,941,988,272.02 |
| 税金及附加 | 20,511,550.98 | 12,358,245.51 | 6,269,786.18 | 25,934,763.52 |
| 销售费用 | 159,677,107.53 | 102,521,894.17 | 45,536,064.26 | 209,683,464.64 |
| 管理费用 | 282,658,510.88 | 177,295,496.33 | 81,217,743.89 | 327,258,947.76 |
| 研发费用 | 38,520,400.73 | 27,332,464.35 | 14,722,082.05 | 49,752,332.31 |
| 财务费用 | 98,515,059.69 | 53,899,803.61 | 24,105,710.03 | 140,374,947.6 |
| 其中:利息费用 | 98,913,622.41 | 54,920,037.01 | 25,325,768.93 | 143,193,949.8 |
| 其中:利息收入 | 2,094,270.69 | 1,888,140.6 | 1,624,872.73 | 4,272,860.74 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 485,810 | -580,430 | 2,613,070 | -161,130 |
| 加:投资收益 | 53,424,320.11 | 42,134,455.95 | 46,198,682.85 | 517,860,172.22 |
| 资产处置收益 | -2,634,568.83 | -2,355,027.41 | -779,754.24 | 359,130.85 |
| 资产减值损失(新) | - | - | - | -60,942,041.88 |
| 信用减值损失(新) | -35,036,813.57 | -22,262,161.07 | -17,883,890.17 | -178,912,409.94 |
| 其他收益 | 20,846,596.13 | 14,303,578.14 | 8,815,119.13 | 39,853,418.8 |
| 四、营业利润 | -469,587,936.52 | -266,630,144.74 | -39,118,890.94 | 97,811,169.75 |
| 加:营业外收入 | 22,552,769.3 | 15,232,762.76 | 7,122,103.97 | 31,061,844.97 |
| 减:营业外支出 | 54,306,135.73 | 11,022,364.98 | 5,995,641.02 | 23,533,518.51 |
| 五、利润总额 | -501,341,302.95 | -262,419,746.96 | -37,992,427.99 | 105,339,496.21 |
| 减:所得税费用 | 12,773,316.27 | 9,281,157.77 | 4,829,842.8 | 15,930,601.85 |
| 六、净利润 | -514,114,619.22 | -271,700,904.73 | -42,822,270.79 | 89,408,894.36 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -514,114,619.22 | -271,700,904.73 | -42,822,270.79 | 89,408,894.36 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -391,760,707.98 | -189,828,495.32 | -13,329,775.76 | 77,621,595.4 |
| 少数股东损益 | -122,353,911.24 | -81,872,409.41 | -29,492,495.03 | 11,787,298.96 |
| 扣除非经常损益后的净利润 | -444,623,256.66 | -251,551,609.99 | -66,549,509.74 | -474,247,516.98 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.15 | -0.07 | -0.01 | 0.03 |
| (二)稀释每股收益 | -0.15 | -0.07 | -0.01 | 0.03 |
| 八、其他综合收益 | -596,271.29 | -432,302.04 | -238,306.09 | 910,416.14 |
| 归属于母公司股东的其他综合收益 | -596,271.29 | -432,302.04 | -238,306.09 | 910,416.14 |
| 九、综合收益总额 | -514,710,890.51 | -272,133,206.77 | -43,060,576.88 | 90,319,310.5 |
| 归属于母公司股东的综合收益总额 | -392,356,979.27 | -190,260,797.36 | -13,568,081.85 | 78,532,011.54 |
| 归属于少数股东的综合收益总额 | -122,353,911.24 | -81,872,409.41 | -29,492,495.03 | 11,787,298.96 |
| 公告日期 | 2026-10-30 | 2026-08-31 | 2026-04-28 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |